ACETAZOLAMIDE ( DrugBank: Acetazolamide )

6 diseases

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02466074 (ClinicalTrials.gov)	August 17, 2016	3/6/2015	Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis	Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis	Multiple Sclerosis	Drug: Acetazolamide;Drug: Placebo	The University of Texas Health Science Center, Houston	NULL	Terminated	18 Years	55 Years	All	6	Phase 2	United States

臨床試験数 : 147 / 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000022686	2016/07/01	01/07/2016	The Clinical Efficacy of Carbonic Anhydrase Inhibitors and Steroids in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa	The Clinical Efficacy of Carbonic Anhydrase Inhibitors and Steroids in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa - The Clinical Efficacy in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa	retinitis pigmentosa	1% dorzolamide eye drop three times daily in each eye 0.1% betamethasone sodium phosphate eye drop three times daily in each eye oral 250mg acetazolamide two tablets daily 40mg triamcinolone acetonide into the sub-Tenon capsule	Kyushu University Hospital	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	40	Not applicable	Japan

臨床試験数 : 1 / 薬物数 : 2 - (DrugBank : 2) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 7

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00839501 (ClinicalTrials.gov)	December 2008	5/2/2009	Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome	Therapeutic Trial of Potassium and Acetazolamide in Andersen-Tawil Syndrome	Andersen-Tawil Syndrome	Dietary Supplement: Potassium;Drug: Acetazolamide	University of Rochester	Office of Rare Diseases (ORD);Rare Diseases Clinical Research Network;National Institute of Neurological Disorders and Stroke (NINDS)	Terminated	10 Years	N/A	Both	3	Phase 1	United States;United Kingdom

臨床試験数 : 1 / 薬物数 : 2 - (DrugBank : 2) / 標的遺伝子数 : 29 - 標的パスウェイ数 : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02904265 (ClinicalTrials.gov)	September 2016	13/9/2016	Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome	Non-inferiority Prospective Randomized Trial of Acetazolamide Versus Diazepam in Patients With Continuous Spike and Wave in Sleep (CSWS)/Landau Kleffner Syndrome (LKS)	Landau-Kleffner Syndrome;Status Epilepticus, Electrographic	Drug: Diazepam;Drug: Acetazolamide	Mayo Clinic	NULL	Terminated	3 Years	12 Years	All	3	Phase 2/Phase 3	United States

臨床試験数 : 15 / 薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-005970-41-NL (EUCTR)	27/02/2012	08/02/2012	The effect of the drug acetazolamide on excessive urine production due to a diminished concentrating ability of the kidney as a result of the use of lithium in patients with an affective disorder: a pilot study	The effect of acetazolamide on lithium-induced nephrogenic diabetes insipidus in patients with an affective disorder: a pilot study	lithium-induced nephrogenic diabetes insipidus MedDRA version: 14.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1;Classification code 10050501;Term: Lithium toxicity;System Organ Class: 10022117 - Injury, poisoning and procedural complications;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]	Trade Name: Acetazolamide Sandoz 250 Other descriptive name: ACETAZOLAMIDE	Radboud University Nijmegen Medical Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands

臨床試験数 : 6 / 薬物数 : 7 - (DrugBank : 4) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 26

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01499485 (ClinicalTrials.gov)	November 2011	20/12/2011	Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation.	Effects of Acetazolamide on the Duration of Mechanical Ventilation in Patients With Metabolic Alkalosis. Phase III Multicenter Double-blinded Clinical Trial.	Pulmonary Disease, Chronic Obstructive;Obesity Hypoventilation Syndrome;Metabolic Alkalosis	Drug: Acetazolamide;Drug: Placebo	Hospital Son Llatzer	NULL	Completed	18 Years	N/A	Both	140	Phase 3	Spain